qualigen THERAPEUTICS Driven to Deliver

Corporate Presentation

Nasdaq: QLGN

August 2021

Forward-Looking Statements

This presentation contains statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including whether preclinical or clinical development of our drugs or therapeutic devices will be successful; whether clinical trials will be approved to begin by or will proceed as contemplated by any projected timeline; whether any drugs or therapeutic devices will receive required regulatory approvals or will be commercially successful; whether we will be able to maintain or expand market demand and/or market share for our diagnostic products; competitive pressures; retaining members of our senior management; and our ability to raise additional funds to finance our operations.

The forward-looking statements included in this presentation represent our views as of the date of this presentation. We anticipate that subsequent events and developments will cause our views to change. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this presentation.

For more information regarding risks and uncertainties that could affect the results of our operations or financial condition, please review our filings with the Securities and Exchange Commission. There can be no assurance that the Company will successfully develop any drugs or therapeutic devices; that clinical trials will be approved to begin by or will proceed as contemplated by the projected timeline; that clinical trial data will be favorable or that such trials will confirm any improvements over other products or lack negative impacts; that any drugs or therapeutic devices will receive required regulatory approvals or that they will be commercially successful; that patents will issue on the Company's owned and in-licensed patent applications; that such patents, if any, and the Company's current owned and in-licensed patents would prevent competition; that the Company will be able to procure or earn sufficient working capital to complete the development, testing and launch of the Company's prospective therapeutic products; or that the Company will be able to maintain or expand market demand and/or market share for the Company's diagnostic products.

Investment Highlights

- Developing novel platform technologies for treatment of cancer and viral diseases
  - Evolution from globally patented and proven diagnostics to therapeutics
- NASDAQ listing and $34 million in equity raised in 2020
- Significant shareholder value drivers expected within the next 12 months:
  - **QN-165**: Initiate and complete enrollment for Phase 1b/2a for COVID-19
  - **QN-247**: Commence IND-enabling studies for lead indication acute myeloid leukemia (AML)
  - **RAS-F**: Identify lead drug candidate and complete pre-IND submission
  - **STARS™**: Evaluate partnerships for patented "blood-cleansing" system leveraging FastPack® science
  - **FastPack®**: Continued revenue and IP expansion for point-of-care diagnostics system

Note: QN-165 (formerly referred to as AS1411), QN-247 (formerly referred to as ALAN or AS1411-GNP)

Evolution From FastPack To Therapeutics

2001 — **Launches** FastPack POC cancer testing system with patented **particle coated** pouch system

2009 — **Refines** expertise in core **particle coating** technology though launch of FastPack IP®

2013 — **Receives** FDA clearance for Vitamin D, the 8th immuno-assay based on **particle coating**

2018 — **Applies** for STARS patent utilizing FastPack **particle coating** science for targeted blood cleansing

2018 — **Licenses** IP from UofL to develop gold **nano-particle coated** AS1411 as anti-cancer drug (ALAN)

2020 — **Expands** **UofL** partnership to include RAS-F anti-cancer platform

2021 — **Licenses** QN-165 from **UofL** as COVID-19 therapeutic and broad-based anti-viral



Figure. Particle coating technology developed in collaboration with University of Louisville (UofL)

Platform Technologies



Comprehensive portfolio of intellectual property covering Qualigen and our platform technologies

**Pancreatic Ductal Adenocarcinoma*

Therapeutics Pipeline

Candidate	Indication	Discovery | Preclin | Phase 1 | Phase 2
QN-165	COVID-19[1]	Antiviral
QN-247	Acute Myeloid Leukemia	Oncology
RAS-F	Pancreatic, colorectal, lung cancers	Oncology
STARS™	Broad-Based Antiviral	Antiviral

(1) QN-165 has potential to be broad based antiviral with COVID-19 as initial indication

Program Milestones



(1) Timeline assumes we move forward with lead compound

QN-165 for COVID-19

- QN-165 is a DNA aptamer and broad-based antiviral drug candidate with initial target indication for the treatment of COVID-19 in hospitalized patients
- Partnered with University of Louisville to exclusively develop for inhibiting or treating COVID-19
- Proof-of-concept *in vitro* studies demonstrate potential to protect cells from the damaging effects of SARS-CoV-2 infection
- QN-165 exhibits an encouraging safety profile(1)
- GMP manufacturing for clinical trials has been secured

(1) QN-165 (formerly referred to as AS1411) was studied in over 100 patients to treat AML and renal cell carcinoma in pre-Qualigen clinical trials and was well tolerated with no SAEs

QN-247 for Acute Myeloid Leukemia (AML)

- QN-247 is an aptamer-based anticancer drug with potential to treat heterogeneous cancer types
- Potency dramatically increases when DNA aptamer is attached to gold nanoparticle
- Initial preclinical studies in breast cancer demonstrated enhanced activity compared to QN-165 alone
  - DNA aptamer QN-165 was well tolerated in prior clinical trials with no SAEs in over 100 cancer patients
- Initial indication targets AML, which as a five-year survival rate of 25% for adults



Figure created by Dr. Mohammad Tariq Malik, University of Louisville

Versatile platform can potentially be leveraged as a monotherapy, radiation-enhancer, imaging resolution agent, or in targeted drug delivery

RAS-F for Advanced Solid Tumors

- RAS is the most common cancer oncogene, present in one quarter of all cancers
  - Activates mutations in one of the three human RAS gene isoforms (KRAS, HRAS or NRAS)
  - Acts as a “hub” that activates multiple effectors; blocking any single pathway is ineffective
- No FDA-approved upstream direct RAS protein-protein inhibitors
- Legacy drugs that target RAS signaling downstream demonstrate minimal clinical activity
- RAS-F is a family of small molecule protein-protein interaction inhibitors that prevent mutated RAS gene proteins from binding to their effector proteins
- Initial indication is pancreatic cancer, followed by other advanced solid tumors such as colorectal and lung cancers

RAS-F Compound F3 Inhibits Tumor Growth



Mice with lung tumor cancer cell injection

Source: Donninger et al. University of Louisville.

STARS™ (Selective Target Antigen Removal System)

- Leverages Qualigen's expertise in advanced reagents and coatings
- Removes disease-associated agents from blood
- Membranes coated with target capture reagents
- Proprietary STARS cartridges designed for use with conventional dialysis or hemofiltration machines
- Initial application as broad-based antiviral system
- Eradicates circulating viruses sufficiently to facilitate patient stabilization and recovery
- Has potential additional applications for patients with sepsis, cancers and inflammation
- Removes immune checkpoints, metastatic cells and inflammation factors

FastPack® Diagnostic System

- Proprietary blood-based diagnostics platform developed by Qualigen and launched in 2001
- Rapid and highly accurate immunoassay testing system with FastPack® Analyzer for use at point of care
- Available in over 1,000 physician offices worldwide
- Over $100 million cumulative sales since launch
- Expanded assay menu of nine tests including tests for prostate cancer, thyroid function, metabolic disorders and research applications

In Summary

- **Products and Pipeline:** Includes novel platform technologies to treat or cure multiple cancer types and viral diseases
- **Resources:** $21.9M* in cash providing runway into mid-2022 to hit significant value driving inflection points starting this year
- **Team:** Experienced and growing leadership team with proven track record in development and commercialization
- **Partnerships:** Leveraging prominent investigators at major research institutions to cost-efficiently advance development
  - Sourcing novel compounds and exploring new indications
- **Value:** Comprehensive global portfolio of intellectual property covering Qualigen and our platform technologies

**As of 3/31/21*

Leadership Team

Michael S. Poirier
Chairman, President & CEO

- Founded Qualigen in 1996
- Previous operations, marketing & commercialization in key roles at Abbott, Sanofi Pasteur and Ashirus Technologies
- Officer in the United States Navy, assigned to the US Atlantic Fleet

Christopher Lotz
VP of Finance & CFO

- Joined Qualigen in 2002
- Previously, held financial leadership roles at rapidly growing companies in the software, manufacturing and media industries

Shishir K. Sinha
VP, Chief Operating Officer

- Joined Qualigen in 2006
- Previously, held leadership roles in the molecular diagnostics industry including Nanogen, Celera Diagnostics and Sequenom

Amy Broidrick
EVP, Chief Strategy Officer

- Joined Qualigen in 2020, initially as independent director on the board
- 26 years in biopharmaceutical industry
- Leadership at Viking Therapeutics, Merck & Co, Pfizer (G.D. Searle) and Arena
- Key roles in strategy and launching and marketing blockbuster and specialty drugs

Tariq Arshad, MD, MBA
SVP, Chief Medical Officer

- Joined Qualigen in 2021
- Oncologist with expertise in both early and late-stage clinical development
- Leadership at Becton Dickinson, Sanofi Genzyme, Humanigen, XOMA, Merck, Genentech, and Pfizer

Wajdi Abdul-Ahad, PhD
VP, R&D, Chief Scientific Officer

- Joined Qualigen in 2006
- Led multifunctional design teams at Beckman Coulter to design over 15 assays
- PhD in Biochemistry from National University of Ireland, Galway

qualigen THERAPEUTICS Driven to Deliver

August 2021